Thursday 17th November 2016
|Text too small?|
Promisia Integrative, which makes a dietary supplement for sore joints, plans to raise $1.3 million in a rights issue at a 40 percent discount for working capital.
Under the offer, the Wellington-based company’s shareholders can apply for one new share for every 10 existing shares as at 5pm on Nov. 25 at 3 cents a share. The stock last traded at 5 cents and has soared 233 percent this year.
Promisia's Arthrem dietary supplement is based on an extract from the plant Artemisia annua. More working capital will allow the company to grow a larger crop, ramp up extraction, and maintain higher levels of raw materials and finished stock, it said.
The rights issue includes an oversubscription facility, it said.
This month Promisia said sales in the first 10 months of the year were $2.2 million and October sales topped $300,000, mainly from New Zealand. At the current monthly rate of sales, the company "achieves breakeven or close to breakeven trading", it said.
Promisia is also developing a canine version of its product which it hopes to launch in the second quarter of 2017.
The proprietary extract made from the medicine herb Artemisia annua was originally tested as a malaria treatment in Papua New Guinea. It is grown for Promisia on a farm in Tanzania.
The shell of what is now Promisia first listed in 1983 as Genestock New Zealand, before becoming first Parapine Timber, then Counterpoint Equities and Savoy Equities, before hiring a brand specialist and rebranding as Promisia in December 2013. At its most recent price, the company has a market value of $23.9 million.
No comments yet
Auckland Airport kicks off next phase of expansion
Cashed-up Plexure eyes acquisitions to accelerate growth as loss shrinks
Tower turns to 1H profit, lifts FY guidance
IRD should have doubled claim against Watson's Cullen Group - Professor
Investore FY profit falls 16% on smaller valuation gain, signals flat dividend for 2020
Synlait receives cease and desist letter regarding Pokeno plant
21st May 2019 Morning Report
NZ dollar steady ahead of central bank speeches
Auditors need to come out of the shadows and explain the value they add: FMA
MARKET CLOSE: NZ shares gain as Liberal win in Australia boosts bank stocks